The dynamic quantification range of the new total-anti-HBc assay allows to distinguish chronic-HBV-infection associated with HBV-induced liver disease, namely chronic-hepatitis-B (CHB), from chronic HBV infection without HBV-induced liver damage, namely non-inflammatory HBeAg-positive and inactive HBeAg-negative phases, independently from HBV-genotypes. Here, KRT88P is linked to chronic hepatitis B virus infection.